Index RUT P/E 14.22 EPS (ttm) 0.18 Insider Own 28.31% Shs Outstand 47.65M Perf Week 2.77%
Market Cap 127.53M Forward P/E 13.22 EPS next Y 0.20 Insider Trans -1.33% Shs Float 35.16M Perf Month -3.70%
Income 8.72M PEG - EPS next Q 0.33 Inst Own 56.92% Short Float 9.89% Perf Quarter -13.04%
Sales 219.14M P/S 0.58 EPS this Y -42.22% Inst Trans -2.07% Short Ratio 7.33 Perf Half Y -51.40%
Book/sh 1.00 P/B 2.60 EPS next Y -24.36% ROA 4.30% Short Interest 3.48M Perf Year -10.34%
Cash/sh 1.97 P/C 1.32 EPS next 5Y - ROE 22.10% 52W Range 2.13 - 7.73 Perf YTD -39.95%
Dividend Est. - P/FCF 3.84 EPS past 5Y - ROI 9.03% 52W High -66.36% Beta 1.08
Dividend TTM - Quick Ratio 1.23 Sales past 5Y -0.59% Gross Margin 73.08% 52W Low 22.07% ATR (14) 0.18
Dividend Ex-Date - Current Ratio 1.32 EPS Y/Y TTM 439.42% Oper. Margin 8.91% RSI (14) 47.40 Volatility 5.35% 6.51%
Employees 185 Debt/Eq 2.03 Sales Y/Y TTM -4.77% Profit Margin 3.98% Recom 3.00 Target Price 4.33
Option/Short Yes / Yes LT Debt/Eq 0.99 EPS Q/Q -308.44% Payout 0.00% Rel Volume 1.26 Prev Close 2.56
Sales Surprise -0.67% EPS Surprise 30.77% Sales Q/Q -13.72% Earnings Aug 01 AMC Avg Volume 474.33K Price 2.60
SMA20 5.50% SMA50 -15.78% SMA200 -39.35% Trades
Volume 596,317 Change 1.56%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-28-21 Upgrade Citigroup
Neutral → Buy
$11
Jun-25-20 Resumed BofA/Merrill
Underperform
$9
Oct-08-19 Downgrade Goldman
Neutral → Sell
$24 → $8
May-10-19 Downgrade Citigroup
Buy → Neutral
$24
May-10-19 Downgrade Cantor Fitzgerald
Overweight → Neutral
$57 → $20
Jan-17-19 Initiated Leerink Partners
Mkt Perform
$21
Jan-03-19 Downgrade Guggenheim
Buy → Neutral
Nov-19-18 Upgrade Goldman
Sell → Neutral
Nov-02-18 Downgrade JP Morgan
Neutral → Underweight
Nov-02-18 Downgrade BofA/Merrill
Buy → Underperform
Oct-01-18 Initiated Cantor Fitzgerald
Overweight
$75
Sep-17-18 Initiated Goldman
Sell
$42
May-11-18 Reiterated Stifel
Buy
$95 → $87
Nov-10-17 Reiterated RBC Capital Mkts
Sector Perform
$92 → $108
Nov-10-17 Reiterated Citigroup
Buy
$156 → $164
Oct-02-17 Reiterated Stifel
Buy
$110 → $130
Sep-11-17 Reiterated Credit Suisse
Outperform
$118 → $136
Jul-10-17 Resumed Leerink Partners
Outperform
$115
Jun-06-17 Reiterated RBC Capital Mkts
Sector Perform
$60 → $88
May-25-17 Reiterated RBC Capital Mkts
Sector Perform
$40 → $60
Show Previous Ratings
Sep-12-24 07:59AM
Sep-03-24 04:15PM
Aug-21-24 05:00AM
Aug-06-24 05:23PM
(Business Wire) +12.26%
-7.44%
Aug-02-24 10:07AM
05:04PM
Loading…
Aug-01-24 05:04PM
(Associated Press Finance)
04:05PM
Jul-23-24 09:40AM
Jul-18-24 04:10PM
Jul-02-24 05:30PM
Jun-07-24 05:37PM
Jun-03-24 02:33PM
Jun-02-24 10:01AM
May-28-24 09:00AM
May-24-24 11:57AM
05:15PM
Loading…
May-23-24 05:15PM
May-20-24 09:59AM
May-03-24 01:09PM
11:31AM
04:02AM
May-02-24 09:55PM
06:05PM
05:48PM
05:12PM
(Associated Press Finance)
04:05PM
Apr-26-24 11:40AM
Apr-25-24 10:02AM
Apr-18-24 04:15PM
Apr-11-24 06:00PM
Apr-03-24 05:30PM
09:25AM
Loading…
Mar-22-24 09:25AM
Mar-20-24 08:30AM
Mar-02-24 08:29AM
Mar-01-24 09:55AM
(Thomson Reuters StreetEvents) -5.31%
09:40AM
09:39AM
Feb-29-24 04:41PM
04:40PM
(Associated Press Finance)
04:05PM
Feb-27-24 06:30PM
11:51AM
Feb-22-24 04:10PM
(Business Wire) -9.22%
+10.83%
Feb-15-24 04:10PM
Feb-13-24 08:30AM
Jan-31-24 12:58PM
Jan-11-24 04:07PM
Jan-06-24 11:02AM
Dec-11-23 08:30AM
Nov-20-23 11:47AM
Nov-06-23 05:15PM
Nov-03-23 12:16PM
09:34AM
(Thomson Reuters StreetEvents)
09:31AM
Nov-02-23 07:42PM
04:47PM
(Associated Press Finance)
04:05PM
Oct-19-23 04:14PM
Oct-14-23 12:30PM
Oct-04-23 05:30PM
Sep-22-23 07:57AM
Sep-21-23 04:10PM
Aug-31-23 04:07PM
Aug-08-23 08:30AM
Aug-04-23 12:36PM
09:23AM
(Thomson Reuters StreetEvents)
Aug-03-23 05:17PM
04:05PM
Jul-20-23 04:15PM
Jun-13-23 09:30AM
Jun-06-23 05:03PM
Jun-04-23 09:00AM
May-28-23 10:06AM
May-22-23 11:07AM
May-05-23 05:15PM
12:45PM
09:44AM
(Thomson Reuters StreetEvents)
May-04-23 05:32PM
04:04PM
Apr-20-23 04:15PM
Apr-17-23 06:49AM
Apr-11-23 05:15PM
Mar-14-23 08:30AM
Mar-06-23 09:48AM
Mar-03-23 05:15PM
02:20PM
06:22AM
(Thomson Reuters StreetEvents)
Mar-02-23 04:05PM
Feb-28-23 04:15PM
Feb-19-23 02:05PM
Feb-16-23 04:31PM
Feb-07-23 05:30PM
Feb-01-23 08:30AM
Jan-25-23 06:19AM
Jan-12-23 04:15PM
Jan-11-23 05:30PM
Jan-09-23 08:55AM
Dec-20-22 08:31AM
Dec-15-22 03:39PM
Dec-07-22 06:03PM
Dec-05-22 05:30PM
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MILLER MICHAEL PATRICK Director Aug 12 '24 Sale 3.49 23,358 81,466 47,000 Aug 13 09:09 PM MILLER MICHAEL PATRICK Director Aug 12 '24 Proposed Sale 3.76 23,358 87,826 Aug 12 09:27 PM NOUGUES MAXIMO F Chief Financial Officer Jul 17 '24 Sale 3.70 4,156 15,382 162,522 Jul 18 07:11 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jul 17 '24 Sale 3.70 2,598 9,615 118,388 Jul 18 07:06 PM HUNT DOUGLAS M See Remarks Jul 17 '24 Sale 3.70 3,637 13,461 133,227 Jul 18 06:57 PM AUERBACH ALAN H President and CEO Jul 17 '24 Sale 3.70 21,920 81,128 7,063,515 Jul 18 06:50 PM NOUGUES MAXIMO F Chief Financial Officer Jul 02 '24 Sale 3.27 5,295 17,307 166,678 Jul 02 09:22 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jul 02 '24 Sale 3.27 6,051 19,778 120,986 Jul 02 09:19 PM HUNT DOUGLAS M See Remarks Jul 02 '24 Sale 3.27 4,349 14,215 136,864 Jul 02 09:15 PM AUERBACH ALAN H President and CEO Jul 02 '24 Sale 3.27 18,885 61,726 7,085,435 Jul 02 09:10 PM WILSON TROY EDWARD Director Jun 13 '24 Sale 3.33 27,000 89,902 350 Jun 17 07:27 PM Stuglik Brian M Director Jun 13 '24 Sale 3.39 9,900 33,528 49,058 Jun 17 07:25 PM Senderowicz Adrian Director Jun 13 '24 Sale 3.33 27,000 89,818 0 Jun 17 07:23 PM MOYES JAY M Director Jun 13 '24 Sale 3.34 22,000 73,467 21,322 Jun 17 07:21 PM Dorval Allison Director Jun 13 '24 Sale 3.37 11,000 37,096 33,000 Jun 17 07:18 PM Wong Alvin F Chief Scientific Officer Dec 04 '23 Sale 3.76 280 1,053 97,934 Jan 10 04:41 PM Wong Alvin F Chief Scientific Officer Jan 03 '24 Sale 4.49 7,733 34,689 98,214 Jan 05 07:03 PM Ludwig Jeffrey Jerome Chief Commercial Officer Jan 03 '24 Sale 4.49 12,956 58,119 99,970 Jan 05 07:00 PM AUERBACH ALAN H President and CEO Jan 03 '24 Sale 4.49 41,396 185,698 6,936,947 Jan 05 06:56 PM NOUGUES MAXIMO F Chief Financial Officer Jan 03 '24 Sale 4.49 15,682 70,348 128,666 Jan 05 06:49 PM HUNT DOUGLAS M See Remarks Jan 03 '24 Sale 4.49 8,358 37,493 103,319 Jan 05 06:42 PM MILLER MICHAEL PATRICK Director Nov 07 '23 Sale 2.83 25,000 70,802 43,358 Nov 09 04:19 PM
Index RUT P/E - EPS (ttm) -2.23 Insider Own 15.28% Shs Outstand 74.35M Perf Week 0.34%
Market Cap 1.61B Forward P/E - EPS next Y -2.62 Insider Trans -0.02% Shs Float 64.93M Perf Month 4.91%
Income -181.75M PEG - EPS next Q -0.63 Inst Own 91.82% Short Float 16.64% Perf Quarter 0.05%
Sales 0.00M P/S - EPS this Y -17.12% Inst Trans 4.34% Short Ratio 16.15 Perf Half Y -1.87%
Book/sh 6.10 P/B 3.44 EPS next Y -7.58% ROA -36.00% Short Interest 10.80M Perf Year 132.78%
Cash/sh 6.41 P/C 3.27 EPS next 5Y 19.93% ROE -39.27% 52W Range 7.41 - 24.17 Perf YTD 45.69%
Dividend Est. - P/FCF - EPS past 5Y -3.94% ROI -37.83% 52W High -13.32% Beta 0.84
Dividend TTM - Quick Ratio 14.94 Sales past 5Y 0.00% Gross Margin - 52W Low 182.73% ATR (14) 0.84
Dividend Ex-Date - Current Ratio 14.94 EPS Y/Y TTM -8.78% Oper. Margin 0.00% RSI (14) 57.73 Volatility 4.31% 3.94%
Employees 142 Debt/Eq 0.04 Sales Y/Y TTM - Profit Margin - Recom 1.23 Target Price 30.27
Option/Short Yes / Yes LT Debt/Eq 0.03 EPS Q/Q -10.18% Payout - Rel Volume 1.49 Prev Close 21.08
Sales Surprise - EPS Surprise 5.77% Sales Q/Q - Earnings Aug 08 AMC Avg Volume 668.79K Price 20.95
SMA20 3.77% SMA50 3.20% SMA200 8.22% Trades
Volume 995,839 Change -0.62%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-22-23 Initiated Mizuho
Buy
$26
Aug-11-23 Initiated BofA Securities
Buy
$31
Jul-27-23 Initiated Scotiabank
Sector Perform
$10.50
May-17-23 Initiated BTIG Research
Buy
$31
Jan-31-23 Initiated Stifel
Buy
$25
Jul-12-22 Initiated Cantor Fitzgerald
Overweight
$30
Feb-15-22 Initiated Jefferies
Buy
$35
May-05-21 Resumed Credit Suisse
Outperform
$42
Apr-26-21 Resumed Credit Suisse
Outperform
$42
Dec-07-20 Reiterated H.C. Wainwright
Buy
$40 → $45
Dec-03-20 Initiated Stifel
Buy
$45
Nov-05-20 Downgrade Piper Sandler
Overweight → Neutral
Jul-07-20 Initiated Credit Suisse
Outperform
$27
May-05-20 Initiated Barclays
Overweight
$24
Jul-18-19 Initiated Deutsche Bank
Buy
$28
Nov-09-18 Initiated Piper Jaffray
Overweight
Aug-01-18 Initiated H.C. Wainwright
Buy
$31
Oct-13-16 Resumed Leerink Partners
Outperform
$15
Jan-22-16 Initiated JMP Securities
Mkt Outperform
Dec-30-15 Initiated Oppenheimer
Outperform
$16
Show Previous Ratings
Sep-17-24 07:30AM
Sep-10-24 07:30AM
Sep-05-24 12:01AM
Sep-02-24 05:22PM
Aug-08-24 04:44PM
(Associated Press Finance)
04:05PM
Loading…
04:05PM
07:30AM
Aug-01-24 07:30AM
Jul-05-24 07:30AM
Jun-24-24 07:30AM
Jun-17-24 09:00AM
Jun-07-24 07:30AM
May-29-24 07:30AM
May-14-24 11:44AM
07:30AM
08:30AM
Loading…
May-08-24 08:30AM
07:30AM
May-06-24 10:14AM
May-03-24 07:30AM
04:03AM
May-02-24 08:58PM
04:48PM
(Associated Press Finance)
04:05PM
Apr-25-24 07:30AM
Apr-22-24 07:30AM
Apr-10-24 07:30AM
Apr-05-24 07:30AM
Mar-06-24 07:30AM
Mar-01-24 05:00PM
Feb-28-24 09:56AM
06:56AM
Loading…
06:56AM
(Thomson Reuters StreetEvents)
Feb-27-24 04:44PM
04:10PM
(Associated Press Finance)
04:01PM
Feb-26-24 07:30AM
Feb-22-24 07:30AM
Feb-20-24 07:30AM
Feb-02-24 07:30AM
Feb-01-24 03:01PM
Jan-30-24 04:07PM
(Investor's Business Daily) +12.10%
07:00AM
Jan-24-24 04:22PM
(Investor's Business Daily) +46.13%
01:16PM
07:00AM
Dec-08-23 07:30AM
Nov-28-23 07:30AM
Nov-05-23 03:44PM
Nov-02-23 06:46PM
(GuruFocus.com) +5.38%
+7.01%
04:36PM
(Associated Press Finance)
04:01PM
07:30AM
Oct-30-23 07:30AM
Oct-26-23 04:05PM
Oct-19-23 07:30AM
Oct-17-23 04:05PM
Oct-09-23 02:03AM
Oct-04-23 12:00PM
07:30AM
Sep-28-23 07:30AM
Sep-19-23 07:30AM
Aug-14-23 07:30AM
Aug-03-23 04:38PM
(Associated Press Finance)
04:05PM
Jul-27-23 07:30AM
Jul-11-23 09:35AM
Jun-14-23 07:00AM
Jun-13-23 04:01PM
Jun-11-23 03:45AM
Jun-05-23 08:02PM
May-30-23 07:30AM
May-23-23 07:30AM
May-13-23 11:51AM
May-11-23 09:35AM
(Thomson Reuters StreetEvents) +8.30%
May-10-23 04:17PM
04:03PM
May-09-23 07:30AM
May-03-23 07:30AM
May-01-23 02:07PM
Apr-18-23 07:30AM
Apr-17-23 07:30AM
Mar-14-23 05:32PM
Mar-01-23 07:30AM
Feb-26-23 06:47AM
Feb-24-23 12:52PM
(Thomson Reuters StreetEvents)
Feb-23-23 04:03PM
Feb-16-23 07:30AM
Feb-12-23 07:14AM
Feb-09-23 07:30AM
Feb-07-23 07:30AM
Jan-31-23 05:43PM
Jan-24-23 07:30AM
Jan-06-23 07:21AM
Dec-12-22 11:34AM
Dec-10-22 10:30AM
Dec-01-22 09:55AM
07:30AM
Nov-22-22 09:40AM
07:30AM
Nov-14-22 09:55AM
Nov-03-22 09:40AM
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bair Teresa Brophy Chief Legal Officer May 20 '24 Sale 22.15 2,615 57,916 68,979 May 20 06:30 PM DOYLE THOMAS JAMES SVP, Finance & Accounting Jan 29 '24 Sale 17.80 2,318 41,262 48,093 Jan 31 05:30 PM Bair Teresa Brophy Chief Legal Officer Jan 29 '24 Sale 17.80 2,053 36,544 68,979 Jan 31 05:30 PM FORD KATHLEEN Chief Operating Officer Jan 29 '24 Sale 17.80 1,496 26,630 21,602 Jan 31 05:30 PM DALE STEPHEN Chief Medical Officer Jan 29 '24 Sale 17.80 7,158 127,416 43,642 Jan 31 05:30 PM DALE STEPHEN Chief Medical Officer Jan 30 '24 Sale 21.55 4,825 103,980 38,817 Jan 31 05:30 PM WILSON TROY EDWARD President and CEO Jan 24 '24 Option Exercise 6.05 91,052 550,594 84,666 Jan 26 05:10 PM WILSON TROY EDWARD President and CEO Jan 24 '24 Sale 20.23 91,052 1,841,982 559 Jan 26 05:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
